抗炎消肿丸在大肠湿热型溃疡性结肠炎患者中的应用  

Application of Kangyan Xiaozhong pills in UC patients with the syndrome of dampness-heat in the large intestines

作　　者：高宗跃 周晓丽[2] GAO Zongyue;ZHOU Xiaoli(Henan Provincial Hospital of Traditional Chinese Medicine/Second Affiliated Hospital of Henan University of Chinese Medicine,Zhengzhou 450000,China;Third Affiliated Hospital of Henan University of Chinese Medicine,Zhengzhou 450008,China)

机构地区：[1]河南省中医院/河南中医药大学第二附属医院,郑州450000 [2]河南中医药大学第三附属医院,郑州450008

出　　处：《吉林中医药》2025年第2期186-190,共5页Jilin Journal of Chinese Medicine

基　　金：2022年度河南省中医药科学研究专项课题(2022ZY2027);2023年度河南省中医药科学研究专项课题(2023ZY2103)。

摘　　要：目的探讨抗炎消肿丸对大肠湿热型溃疡性结肠炎(ulcerative colitis,UC)患者肠黏膜屏障及肠道微生态的影响。方法选取大肠湿热型溃疡性结肠炎患者92例,收集时间为2022年10月—2023年9月,收集地点为河南省中医院,随机将患者分为对照组和治疗组,各46例。2组均给予常规对症治疗,对照组在此基础上口服美沙拉嗪肠溶片,治疗组在对照组的基础上口服抗炎消肿丸,2组均治疗6周。比较2组治疗6周后的疗效,治疗前和治疗6周后的临床症状相关评分、肠黏膜屏障功能相关指标、肠道微生态变化情况、炎性因子水平及不良反应。结果治疗组治疗6周后的总有效率较对照组高(93.48%vs.78.26%,P<0.05)。2组治疗6周后的临床症状积分、Baron评分、改良Mayo评分、血清DAO、D-LAC、LPS、TNF-α、IL-1、IL-6水平及肠杆菌、肠球菌含量较治疗前降低,治疗组更低;双歧杆菌、乳酸杆菌及血清IL-10水平升高,治疗组更高(P<0.05)。治疗组和对照组治疗期间的不良反应总发生率比较差异无统计学意义(10.87%vs.17.39%,P>0.05)。结论抗炎消肿丸可减轻大肠湿热型溃疡性结肠炎患者机体炎症,改善肠黏膜屏障及肠道微生态,进而可促进症状的改善,提高疗效,且安全性良好。Objective To investigate the effects of Kangyan Xiaozhong pills on the intestinal mucosal barrier and gut microbiota in UC patients with the syndrome of dampness-heat in the large intestines.Methods A total of 92 UC patients with the syndrome of dampness-heat in the large intestines were selected as the study subjects from October 2022 to September 2023 at the Henan Provincial Hospital of Traditional Chinese Medicine,and they were randomly divided into a control group and a treatment group,each with 46 cases.Both groups were given conventional symptomatic treatment,and the control group took additionally mesalazine enteric-coated tablets orally,while the treatment group took Kangyan Xiaozhong pills orally on the basis of the control group,both for 6 weeks.The efficacy after 6 weeks of treatment,the scores of related clinical symptoms,related indicators of the intestinal mucosal barrier function,changes in gut miocrobiota,levels of inflammatory factors before and after 6 weeks of treatment and adverse reactions were compared between the two groups.Results The overall effective rate was higher in the treatment group than that in the control group after 6 weeks of treatment(93.48%vs.78.26%,P<0.05).The clinical symptom scores,Baron scores,modified Mayo scores,the serum levels of DAO,D-LAC,LPS,TNF-α,IL-1,IL-6,and the contents of enterobacteriaceae and enterococci were decreased in both groups after 6 weeks of treatment,and the above indicators were much lower in the treatment group,while the levels of bifidobacteria,lactobacillus and serum IL-10 were increased in both groups,and they were much higher in the treatment group(P<0.05).There was no statistically significant difference in the total incidence of adverse reactions between the treatment group and the control group during the treatment period(10.87%vs.17.39%,P>0.05).Conclusion Kangyan Xiaozhong pills can alleviate the body inflammation in UC patients with the syndrome of dampness-heat in the large intestines,improve their intestinal mucosal barrier and intesti

关 键 词：溃疡性结肠炎 大肠湿热型 抗炎消肿丸 肠黏膜屏障 肠道微生态 

分 类 号：R574.62[医药卫生—消化系统]